AstraZeneca Reports Phase III Success for Baxdrostat in Hypertension

AstraZeneca today announced positive phase III clinical data for baxdrostat, an investigational oral therapy being developed for patients with uncontrolled or resistant hypertension.

The results strengthen baxdrostat’s position as a potential next-generation treatment option for patients whose blood pressure remains high despite standard therapies.

The BaxHTN phase III clinical trial data were presented at the European Society of Cardiology Congress and concurrently published in the New England Journal of Medicine. In November at the American Heart Association Global Conference, findings from the Bax24 study, a separate Phase III clinical trial, were also presented which supports the overall clinical profile of baxdrostat.

Also Read: Advanced Formulation Technologies Streamlining Global Pharma Innovation

According to the National Health Mission, approximately 57 percent of all stroke deaths and 24 percent of all coronary deaths are associated with uncontrolled blood pressure. While many medications are available to control high blood pressure, there is still a major clinical unmet need as both treatment and control rates remain low.

Baxdrostat works by directly inhibiting aldosterone and offers a more targeted form of therapy for people who have difficulty controlling their blood pressure. In the BaxHTN study, patients receiving 2 mg of baxdrostat experienced a reduction of 9.8 mmHg from baseline to week 12 compared to those receiving a placebo, achieving the primary endpoint. Moreover, all key secondary endpoints, including reductions in diastolic blood pressure and greater proportions of patients achieving their target blood pressures, were also met.

Speaking on the importance of these results, Dr Sandeep Arora, director medical affairs, AstraZeneca India, said, “These results add to the growing body of evidence supporting aldosterone synthase inhibition as a promising approach…inform early monitoring strategies, and assess long-term durability of blood pressure reduction and impact on cardiovascular outcomes.”

AstraZeneca said ongoing research will focus on patient selection, early monitoring, and long-term cardiovascular outcomes to support the future role of baxdrostat in resistant hypertension care.